Literature DB >> 16172519

Rationale for the potential use of calcitonin in osteoarthritis.

D H Manicourt1, J P Devogelaer, M Azria, S Silverman.   

Abstract

This review provides evidence that osteoarthritis (OA) or a major subset of OA is not only a disease of cartilage but also a disorder of subchondral bone. This review also discusses the potential efficacy of a bone and cartilage active agent, calcitonin, and discusses how calcitonin might be useful in the pharmaceutical treatment of OA.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16172519

Source DB:  PubMed          Journal:  J Musculoskelet Neuronal Interact        ISSN： 1108-7161            Impact factor:   2.041


  10 in total

1.  Converting the highly amyloidogenic human calcitonin into a powerful fibril inhibitor by three-dimensional structure homology with a non-amyloidogenic analogue.

Authors:  Giuseppina Andreotti; Rosa Maria Vitale; Carmit Avidan-Shpalter; Pietro Amodeo; Ehud Gazit; Andrea Motta
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

2.  Oral calcitonin.

Authors:  Michael J Maricic
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

Review 3.  Salmon calcitonin: a review of current and future therapeutic indications.

Authors:  C H Chesnut; M Azria; S Silverman; M Engelhardt; M Olson; L Mindeholm
Journal:  Osteoporos Int       Date:  2007-12-11       Impact factor: 4.507

4.  Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation.

Authors:  Svenja Sladek; Clodagh Kearney; Daniel Crean; Pieter A J Brama; Lidia Tajber; Karolina Fawcett; Margot C Labberte; Bernadette Leggett; David J Brayden
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

5.  Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis--the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation.

Authors:  M A Karsdal; I Byrjalsen; A C Bay-Jensen; K Henriksen; B J Riis; C Christiansen
Journal:  BMC Musculoskelet Disord       Date:  2010-06-17       Impact factor: 2.362

6.  Effects of calcitonin on knee osteoarthritis and quality of life.

Authors:  Meltem Esenyel; Afitap İçağasıoğlu; Cem Zeki Esenyel
Journal:  Rheumatol Int       Date:  2012-03-28       Impact factor: 2.631

7.  Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy.

Authors:  Morten A Karsdal; Inger Byrjalsen; Kim Henriksen; Bente J Riis; Claus Christiansen
Journal:  Eur J Clin Pharmacol       Date:  2009-10-08       Impact factor: 2.953

8.  The association of single nucleotide polymorphisms in the calcitonin gene with primary osteoarthritis of the knee in Mexican mestizo population.

Authors:  J J Magaña; B Muñoz; V M Borgonio-Cuadra; C Razo-Estrada; C González-Huerta; S Cortés-González; A Albores; A Miranda-Duarte
Journal:  Rheumatol Int       Date:  2013-04-11       Impact factor: 2.631

9.  Fibrillation of Human Calcitonin and Its Analogs: Effects of Phosphorylation and Disulfide Reduction.

Authors:  Harshil K Renawala; Karthik B Chandrababu; Elizabeth M Topp
Journal:  Biophys J       Date:  2020-11-18       Impact factor: 4.033

10.  Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13.

Authors:  Christelle Boileau; Johanne Martel-Pelletier; Judith Caron; Philippe Msika; Georges B Guillou; Caroline Baudouin; Jean-Pierre Pelletier
Journal:  Arthritis Res Ther       Date:  2009-03-16       Impact factor: 5.156
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.